Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Overview of attention for article published in Frontiers in Cell and Developmental Biology, October 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,274 followers.

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro. #lymphoma #lymsm https://t.co/eHKLc5vEtU

11 Nov 2020

Reply Repost Favourite

New article: Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro. https://t.co/10yJZJVZW5 #TCL #lymsm #hematology https://t.co/eUoHG5

10 Nov 2020

Reply Repost Favourite

New Research: Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro: Pralatrexate (Folotyn; PLX) and belinostat… https://t.co/SMdGxxo9K

09 Oct 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.